TrialWorld journal of stem cells2024

Safety and efficiency of Wharton's Jelly-derived mesenchymal stem cell administration in patients with traumatic brain injury: First results of a phase I study.

Serdar Kabatas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.